摘要
目的：研、究基因工程干扰素－γ对类风湿关节炎的疗效及安全性。方法：为双盲对照试验，１００例类风湿关节炎病人，随机分成试验组与安慰剂组，每组各５０例。试验组病人肌内注射（肌注）干扰素－γ １００万 ＩＵ，ｑｄ， １ｍｏ后改为 ２００万 ＩＵ，ｑｏｄ，总疗程为３ｍｏ。对照组肌注含２％清蛋白的０．９％氯化钠注射液。结果：干扰素－γ对类风湿关节炎的有效率为６０％，显著高于对照组，后者为１２％（Ｐ＜０．０１）。经干扰素治疗后，Ｃ反应蛋白也有显著下降。干扰素－γ的主要不良反应为发热（２６％），一般见于疗程初期，能自行缓解，没有发现严重的毒副反应。结论：基因工程干扰素－γ是一种有效且安全的治疗类风湿关节炎的新型生物制剂。
AIM: To study the efficacy and safety of genetic engineering interferon-gamma (IFN-r) for treatment of rheumatoid arthritis (RA). METHODS: This was a double blind, control stUdy. One hundred patients with RA were randomly allocated into IFN-r group and control group (50 patients for each). IFN-r one million units was injected intramuscularly to each patient in IFN-r group every day for 1 mo, then two million units every other day for another 2 mo. For the controls, 0. 9% sodium chloride injection containing 2% albumin was injected intramuscularly as the manner of IFN--r group. RESULTS: The efficacy rate Of IFN-r group was 60%, significantly higher than the control group (12 % ) (P <0. 01). Joint pain, swelling and morning stiffness in IFN-r group greatly improved. Laboratory parameters such as CRP got much improved too. The major adverse reaction for IFN--r was fever which could be relieved spontaneously for most of the Patients as the therapy continued. CONCLUSION: IFN-r is an effective and safety medicine for treatment of rheumatoid arthritis.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2000年第2期87-89,共3页
Chinese Journal of New Drugs and Clinical Remedies
关键词
干扰素类
类风湿性关节炎
药物疗法
interferons
rheumatoid arthritis
double -- blind method
drug therapy
